Enovis Corporation (LON:0I1B)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 1.05B -13.1% |
| Revenue (ttm) | 1.72B +4.9% |
| Net Income | -825.00M |
| EPS | -14.39 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 6.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 71 |
| Open | 24.28 |
| Previous Close | 24.72 |
| Day's Range | 23.38 - 24.28 |
| 52-Week Range | 19.20 - 33.45 |
| Beta | 1.45 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Enovis
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary ca... [Read more]
Financial Performance
In 2025, Enovis's revenue was $2.25 billion, an increase of 6.66% compared to the previous year's $2.11 billion. Losses were -$1.18 billion, 43.5% more than in 2024.
Financial numbers in USD Financial StatementsNews
Enovis price target raised to $30 from $29 at BMO Capital
BMO Capital analyst Vik Chopra raised the firm’s price target on Enovis (ENOV) to $30 from $29 and keeps an Outperform rating on the shares.
Enovis Earnings Call Transcript: Q2 2026
Q2 2026 delivered 5% organic growth, margin expansion, and strong free cash flow, driven by new product launches and commercial execution. Guidance for 2026 is reaffirmed, with expectations for continued growth, margin improvement, and cash flow as integration costs decline.
Enovis Earnings release: Q2 2026
Enovis released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Enovis Slides: Q2 2026
Enovis has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Enovis Quarterly report: Q2 2026
Enovis has published its Q2 2026 quarterly earnings report on August 6, 2026.
Enovis reports Q2 adjusted EPS 90c, consensus 85c
Reports Q2 revenue $583M, consensus $581.84M. “Our second-quarter results reflect a more focused organization and a portfolio that has been meaningfully reshaped over the past several years,” said Dam...
Enovis backs FY26 adjusted EPS view $3.52-$3.73, consensus $3.64
Enovis (ENOV) reaffirmed financial expectations for 2026. Revenue is expected to be in a range of $2.31B-2.37B, which incorporates 4%-6% organic revenue growth. FY26 consensus $2.34B. Adjusted EBITDA ...
Enovis Announces Second Quarter 2026 Results
Second-quarter sales growth of 3% on a reported basis, 5% organic Second-quarter Reconstructive sales grew 8% on a reported basis, 6% organic Reaffirmed full-year 2026 guidance for revenue, adjusted E...
Enovis assumed with a Buy at UBS
UBS assumed coverage of Enovis (ENOV) with a Buy rating with a price target of $51, up from $50. Concerns over Enovis’s Lima integration and free cash flow are easing,…
Enovis to Host Second Quarter 2026 Results Conference Call on August 6th
Dallas, TX, July 17, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and liv...
Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
DALLAS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology company, today announced the U.S. launch of CT-RevitL™, the next-generation vete...
BMO starts Enovis at Outperform on accelerating free cash flow conversion
BMO Capital initiated coverage of Enovis (ENOV) with an Outperform rating and $29 price target The firm believes Enovis is entering a period of accelerating free cash flow conversion, improving…
Enovis initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Enovis (ENOV) with an Outperform rating and $29 price target
Enovis price target lowered to $32 from $36 at Evercore ISI
Evercore ISI lowered the firm’s price target on Enovis (ENOV) to $32 from $36 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life Sciences…
Enovis Launches Spinamic® Hybrid Scoliosis Brace, Combining Corrective Performance with Improved Wearability for Children and Teens
The DonJoy Spinamic® Hybrid Scoliosis Brace is a first-of-its-kind device that integrates rigid corrective elements into a breathable, adjustable design to improve both clinical outcomes and patient c...
Enovis Transcript: AGM 2026
The meeting, held virtually for broader access, covered four agenda items, including director elections and key proposals. All nominees and proposals received majority approval, with no questions raised by stakeholders.
Enovis price target raised to $36 from $35 at Evercore ISI
Evercore ISI raised the firm’s price target on Enovis (ENOV) to $36 from $35 and keeps an Outperform rating on the shares.
Enovis price target lowered to $37 from $45 at Baird
Baird analyst Jeffrey Johnson lowered the firm’s price target on Enovis (ENOV) to $37 from $45 and keeps an Outperform rating on the shares. The firm updated its model following…
Enovis Earnings Call Transcript: Q1 2026
Q1 2026 saw 5% sales growth, strong execution in both segments, and robust innovation momentum. Adjusted EPS rose 10% year-over-year, with margin improvement and reaffirmed 2026 guidance despite macro and cost headwinds.
Enovis Earnings release: Q1 2026
Enovis released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Enovis Slides: Q1 2026
Enovis has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Enovis Quarterly report: Q1 2026
Enovis has published its Q1 2026 quarterly earnings report on May 7, 2026.
Enovis reports Q1 adjusted EPS 89c, consensus 81c
Reports Q1 revenue $589M, consensus $572.44M. “Our first-quarter results reflect solid execution and continued progress advancing our innovation-led strategy,” said Damien McDonald, Chief Executive Of...
Enovis backs FY26 adjusted EPS view $3.52-$3.73, consensus $3.63
Enovis (ENOV) reaffirms financial expectations for 2026. Revenue is expected to approximate $2.31B-2.37B, which incorporates 4-6% organic revenue growth, consensus $2.34B. Adjusted EBITDA is expected ...
Enovis Announces First Quarter 2026 Results
Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results...